Beddingfield III Frederick 4
4 · Sienna Biopharmaceuticals, Inc. · Filed Aug 1, 2017
Insider Transaction Report
Form 4
Beddingfield III Frederick
DirectorPresident & CEO
Transactions
- Conversion
Series A-3 Preferred Stock
2017-08-01−14,076→ 0 total(indirect: See Footnote)→ Common Stock (14,076 underlying) - Conversion
Series A-3 Preferred Stock
2017-08-01−112,614→ 0 total(indirect: See Footnote)→ Common Stock (112,614 underlying) - Conversion
Common Stock
2017-08-01+14,076→ 14,076 total(indirect: See Footnote) - Conversion
Series A-3 Preferred Stock
2017-08-01−14,076→ 0 total(indirect: See Footnote)→ Common Stock (14,076 underlying) - Conversion
Common Stock
2017-08-01+14,076→ 14,076 total(indirect: See Footnote) - Conversion
Common Stock
2017-08-01+112,614→ 112,614 total(indirect: See Footnote)
Holdings
- 553,652
Common Stock
Footnotes (5)
- [F1]The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
- [F2]The shares are directly held by Beddingfield Children's Trust fbo Catherine Sara Beddingfield.
- [F3]The shares are directly held by Beddingfield Children's Trust fbo Claire Elizabeth Beddingfield.
- [F4]The shares are directly held by the Beddingfield Family Trust.
- [F5]The expiration date is not relevant to the conversion of these securities.